pioglitazone has been researched along with Carcinoma, Hepatocellular in 16 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Carcinoma, Hepatocellular: A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Pioglitazone, vitamin E, a weight reduction program, and usual care were investigated, with the outcomes of interest being the number of cirrhosis and hepatocellular carcinoma (HCC) cases, life expectancy, quality-adjusted life-years (QALYs), lifetime costs, and the incremental cost-effectiveness ratios (ICERs)." | 7.91 | Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-Alcoholic Fatty Liver Disease in Thailand. ( Chaiyakunapruk, N; Chongmelaxme, B; Dilokthornsakul, P; Phisalprapa, P; Sawangjit, R, 2019) |
| "Pioglitazone treatment started at the first signs of fibrosis in both models." | 5.51 | Pioglitazone Reduces Hepatocellular Carcinoma Development in Two Rodent Models of Cirrhosis. ( Arora, G; Baumert, TF; Erstad, DJ; Fuchs, BC; Ghoshal, S; Hoshida, Y; Lanuti, M; Li, S; Masia, R; Sojoodi, M; Tanabe, KK, 2019) |
| "Glyburide did not increase basal or insulin-stimulated DNA synthesis." | 5.30 | Pioglitazone: in vitro effects on rat hepatoma cells and in vivo liver hypertrophy in KKAy mice. ( Diani, A; Messina, JL; Murray, FT; Sangani, GA; Wachowski, MB; Weinstock, RS, 1997) |
| " Pioglitazone, vitamin E, a weight reduction program, and usual care were investigated, with the outcomes of interest being the number of cirrhosis and hepatocellular carcinoma (HCC) cases, life expectancy, quality-adjusted life-years (QALYs), lifetime costs, and the incremental cost-effectiveness ratios (ICERs)." | 3.91 | Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-Alcoholic Fatty Liver Disease in Thailand. ( Chaiyakunapruk, N; Chongmelaxme, B; Dilokthornsakul, P; Phisalprapa, P; Sawangjit, R, 2019) |
| "Systemic therapy for advanced hepatocellular carcinoma (HCC) is still challenging." | 2.84 | Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trial. ( Andreesen, R; Endlicher, E; Ghibelli, L; Hackl, C; Herr, W; Klebl, F; Reichle, A; Schulz, U; Vogelhuber, M; Walter, I; Wiedmann, K; Wiest, R, 2017) |
| "NASH, the more aggressive form of NAFLD, may progress to cirrhosis and hepatocellular carcinoma." | 2.55 | Therapies in non-alcoholic steatohepatitis (NASH). ( Oseini, AM; Sanyal, AJ, 2017) |
| "Although a correlation between pancreatic cancer and diabetes mellitus has long been suspected, the potential role diabetes mellitus plays in the pathogenicity of both hepatocellular carcinoma and colon cancer is becoming increasingly well defined." | 2.50 | Diabetes mellitus as a novel risk factor for gastrointestinal malignancies. ( Herrigel, DJ; Moss, RA, 2014) |
| "Nonalcoholic fatty liver disease (NAFLD) is considered the most common liver disorder in the Western world." | 2.49 | Nonalcoholic fatty liver disease: current issues and novel treatment approaches. ( Bril, F; Cusi, K; Lomonaco, R; Sunny, NE, 2013) |
| "Pioglitazone treatment started at the first signs of fibrosis in both models." | 1.51 | Pioglitazone Reduces Hepatocellular Carcinoma Development in Two Rodent Models of Cirrhosis. ( Arora, G; Baumert, TF; Erstad, DJ; Fuchs, BC; Ghoshal, S; Hoshida, Y; Lanuti, M; Li, S; Masia, R; Sojoodi, M; Tanabe, KK, 2019) |
| "Pioglitazone (PGZ) is an agonist of peroxisome proliferator-activated receptor gamma (PPARg), itself a member of the nuclear receptor superfamily, responsible for the modulation of a number of metabolic pathways, including cell differentiation, metabolism of lipids and inflammation." | 1.37 | Chemoprevention of hepatocellular carcinoma. Proof of concept in animal models. ( Borbath, I; Stärkel, P, 2011) |
| "Pioglitazone treatment was initiated the day after the first diethylnitrosamine injection." | 1.34 | The PPARgamma agonist pioglitazone inhibits early neoplastic occurrence in the rat liver. ( Borbath, I; Horsmans, Y; Leclercq, I; Moulin, P; Sempoux, C, 2007) |
| " Genes that are differentially expressed between the more toxic troglitazone/ciglitazone group and the less toxic rosiglitazone/pioglitazone group are involved in necrotic, apoptotic, and cell proliferative pathways." | 1.33 | Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR gamma agonists on rat primary hepatocytes and human HepG2 cells. ( Blann, E; Dial, S; Dragan, YP; Guo, L; Muskhelishvili, L; Schroth, G; Shi, L; Sun, Y; Zhang, L, 2006) |
| "Troglitazone is an antidiabetic agent that increases the insulin sensitivity of target tissues in non-insulin-dependent diabetes mellitus." | 1.31 | Cytotoxicity and apoptosis produced by troglitazone in human hepatoma cells. ( Nakajima, M; Yamamoto, Y; Yamazaki, H; Yokoi, T, 2001) |
| "Glyburide did not increase basal or insulin-stimulated DNA synthesis." | 1.30 | Pioglitazone: in vitro effects on rat hepatoma cells and in vivo liver hypertrophy in KKAy mice. ( Diani, A; Messina, JL; Murray, FT; Sangani, GA; Wachowski, MB; Weinstock, RS, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 4 (25.00) | 29.6817 |
| 2010's | 10 (62.50) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, S | 1 |
| He, K | 1 |
| Tian, C | 1 |
| Sun, H | 1 |
| Zhu, C | 1 |
| Bai, S | 1 |
| Liu, J | 1 |
| Wu, Q | 1 |
| Xie, D | 1 |
| Yue, T | 1 |
| Shen, Z | 1 |
| Dai, Q | 1 |
| Yu, X | 1 |
| Zhu, S | 1 |
| Liu, G | 1 |
| Zhou, R | 1 |
| Duan, S | 1 |
| Tian, Z | 1 |
| Xu, T | 1 |
| Wang, H | 1 |
| Bai, L | 1 |
| Walter, I | 1 |
| Schulz, U | 1 |
| Vogelhuber, M | 1 |
| Wiedmann, K | 1 |
| Endlicher, E | 1 |
| Klebl, F | 1 |
| Andreesen, R | 1 |
| Herr, W | 1 |
| Ghibelli, L | 1 |
| Hackl, C | 1 |
| Wiest, R | 1 |
| Reichle, A | 1 |
| Li, S | 1 |
| Ghoshal, S | 1 |
| Sojoodi, M | 1 |
| Arora, G | 1 |
| Masia, R | 1 |
| Erstad, DJ | 1 |
| Lanuti, M | 1 |
| Hoshida, Y | 1 |
| Baumert, TF | 1 |
| Tanabe, KK | 1 |
| Fuchs, BC | 1 |
| Chongmelaxme, B | 1 |
| Phisalprapa, P | 1 |
| Sawangjit, R | 1 |
| Dilokthornsakul, P | 1 |
| Chaiyakunapruk, N | 1 |
| Li, LJ | 1 |
| Li, GD | 1 |
| Wei, HL | 1 |
| Chen, J | 1 |
| Liu, YM | 1 |
| Li, F | 1 |
| Xie, B | 1 |
| Wang, B | 1 |
| Li, CL | 1 |
| Yang, Y | 1 |
| Zhao, LH | 1 |
| Huang, B | 1 |
| Wang, RY | 1 |
| Yuan, SX | 1 |
| Tao, QF | 1 |
| Xu, Y | 1 |
| Sun, HY | 1 |
| Lin, C | 1 |
| Zhou, WP | 1 |
| Herrigel, DJ | 1 |
| Moss, RA | 1 |
| Oseini, AM | 1 |
| Sanyal, AJ | 1 |
| Shim, J | 1 |
| Kim, BH | 1 |
| Kim, YI | 1 |
| Kim, KY | 1 |
| Hwangbo, Y | 1 |
| Jang, JY | 1 |
| Dong, SH | 1 |
| Kim, HJ | 1 |
| Chang, YW | 1 |
| Chang, R | 1 |
| Borbath, I | 2 |
| Stärkel, P | 1 |
| Lomonaco, R | 1 |
| Sunny, NE | 1 |
| Bril, F | 1 |
| Cusi, K | 1 |
| Füessl, HS | 1 |
| Guo, L | 1 |
| Zhang, L | 1 |
| Sun, Y | 1 |
| Muskhelishvili, L | 1 |
| Blann, E | 1 |
| Dial, S | 1 |
| Shi, L | 1 |
| Schroth, G | 1 |
| Dragan, YP | 1 |
| Leclercq, I | 1 |
| Moulin, P | 1 |
| Sempoux, C | 1 |
| Horsmans, Y | 1 |
| Weinstock, RS | 1 |
| Murray, FT | 1 |
| Diani, A | 1 |
| Sangani, GA | 1 |
| Wachowski, MB | 1 |
| Messina, JL | 1 |
| Yamamoto, Y | 1 |
| Nakajima, M | 1 |
| Yamazaki, H | 1 |
| Yokoi, T | 1 |
3 reviews available for pioglitazone and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Diabetes mellitus as a novel risk factor for gastrointestinal malignancies.
Topics: Adenocarcinoma; Carcinoma, Hepatocellular; Colorectal Neoplasms; Diabetes Complications; Humans; Hyp | 2014 |
Therapies in non-alcoholic steatohepatitis (NASH).
Topics: Carcinoma, Hepatocellular; Diet; Disease Progression; Exercise; Fibrosis; Humans; Hypoglycemic Agent | 2017 |
Nonalcoholic fatty liver disease: current issues and novel treatment approaches.
Topics: Carcinoma, Hepatocellular; Fatty Liver; Humans; Hypoglycemic Agents; Insulin Resistance; Non-alcohol | 2013 |
1 trial available for pioglitazone and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trial.
Topics: Administration, Metronomic; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols | 2017 |
12 other studies available for pioglitazone and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Impaired lipid biosynthesis hinders anti-tumor efficacy of intratumoral iNKT cells.
Topics: Animals; Carcinoma, Hepatocellular; Cholesterol; Galactosylceramides; Gene Expression Regulation; Hu | 2020 |
Pioglitazone Reduces Hepatocellular Carcinoma Development in Two Rodent Models of Cirrhosis.
Topics: Adiponectin; AMP-Activated Protein Kinases; Animals; Carcinoma, Hepatocellular; Choline; Diet, High- | 2019 |
Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-Alcoholic Fatty Liver Disease in Thailand.
Topics: Carcinoma, Hepatocellular; Cost-Benefit Analysis; Humans; Hypoglycemic Agents; Liver Cirrhosis; Live | 2019 |
Insulin resistance reduces sensitivity to Cis-platinum and promotes adhesion, migration and invasion in HepG2 cells.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Adhesion; Cell Line, Tumor; Cell Movement; Ce | 2014 |
Pioglitazone, a PPARγ agonist, inhibits growth and invasion of human hepatocellular carcinoma via blockade of the rage signaling.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Female; Hep | 2015 |
The peroxisome proliferator-activated receptor gamma ligands, pioglitazone and 15-deoxy-Delta(12,14)-prostaglandin J(2), have antineoplastic effects against hepatitis B virus-associated hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Caspase 9; Cell Line, Tumor; | 2010 |
Chemoprevention of hepatocellular carcinoma. Proof of concept in animal models.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Models, Animal; Farnesol; Humans; | 2011 |
[Fatty liver. Not only ultrasound to be relied on!].
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Fatty Liver; Female; Hepatitis; Hepatitis C; Hep | 2003 |
Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR gamma agonists on rat primary hepatocytes and human HepG2 cells.
Topics: Animals; Carcinoma, Hepatocellular; Cells, Cultured; Chromans; Cluster Analysis; Gene Expression Pro | 2006 |
The PPARgamma agonist pioglitazone inhibits early neoplastic occurrence in the rat liver.
Topics: 2-Acetylaminofluorene; Animals; Anticarcinogenic Agents; Apoptosis; Blotting, Western; Carcinogens; | 2007 |
Pioglitazone: in vitro effects on rat hepatoma cells and in vivo liver hypertrophy in KKAy mice.
Topics: Animals; Blood Glucose; Body Weight; Carcinoma, Hepatocellular; Cell Division; Diabetes Mellitus, Ty | 1997 |
Cytotoxicity and apoptosis produced by troglitazone in human hepatoma cells.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Survival; Chromans; DNA Fragmentation; Dose-Response Rela | 2001 |